Cytosorbents CORP Form 4 insider transactions

Cytosorbents Corp. Chief Financial Officer Peter J. Mariani acquired 100,000 shares of common stock through an open market purchase.

CytoSorbents Corporation CEO Phillip P. Chan acquired 261,469 shares of common stock through open market purchases.

Cytosorbents Corporation's CEO, Phillip P. Chan, purchased 100,000 shares of common stock in an open market transaction.

Cytosorbents Corporation's CEO, Phillip P. Chan, was granted 105,600 restricted stock units and 136,400 stock options as part of his compensation.

Cytosorbents Director Edward R. Jones acquired 22,000 stock options and holds 88,834 common shares and RSUs, as detailed in a recent SEC filing.

Cytosorbents Corporation Director Michael G. Bator reported the grant of 44,000 stock options and updated his beneficial ownership of common stock and restricted stock units.

Cytosorbents' Chief Financial Officer, Peter J. Mariani, acquired 71,500 restricted stock units and 90,000 stock options, increasing his beneficial ownership.

Cytosorbents Director Jiny Kim reported beneficial ownership of 77,819 common shares and was granted 22,000 stock options.

Cytosorbents Corporation's President and COO, Vincent Capponi, was granted 89,100 restricted stock units and 111,100 stock options, effective August 8, 2025.

Cytosorbents' Chief Medical Officer, Efthymios Deliargyris, received 70,000 restricted stock units and 95,000 stock options, aligning executive incentives with company performance.

Cytosorbents Director Alan D. Sobel filed a Form 4 detailing his beneficial ownership of common stock and stock options, including restricted stock units and a new option grant.

Director Michael G. Bator exercised subscription rights to acquire Cytosorbents shares and warrants, while a portion of Series A warrants expired unexercised.

Vincent Capponi, President and COO of Cytosorbents Corp, reports exercising subscription rights and warrants, while also disclosing holdings of common stock and restricted stock units.

Peter J. Mariani, CFO of Cytosorbents Corp, reports acquiring common stock and warrants through a rights offering.

Phillip Chan, CEO of Cytosorbents, reports the acquisition of common stock and Series A Right Warrants through a rights offering, as well as the expiration of unexercised warrants.

Director Alan D. Sobel reports acquiring shares and warrants of CytoSorbents Corporation through a rights offering.

Michael G. Bator, a director at Cytosorbents Corp, exercised subscription rights to acquire common stock and warrants.

Cytosorbents Corp's President and COO, Vincent Capponi, exercised subscription rights to acquire shares and warrants as part of a recent rights offering.

Cytosorbents' Chief Medical Officer, Efthymios Deliargyris, exercised subscription rights, acquiring 16,233 shares of common stock and warrants.

Alan D. Sobel, a director at Cytosorbents Corp, exercised subscription rights to acquire shares and warrants, increasing his holdings in the company.

Cytosorbents CEO Phillip P. Chan exercised subscription rights to acquire shares and warrants, increasing his stake in the company.

Cytosorbents' Chief Financial Officer, Peter J. Mariani, exercised subscription rights to acquire shares and warrants in the company.

Cytosorbents' Chief Financial Officer, Peter Mariani, recently purchased 20,000 shares of the company's common stock on the open market.

Cytosorbents' Chief Financial Officer, Peter Mariani, has recently acquired additional shares of the company's common stock through open market purchases.

Efthymios Deliargyris, Chief Medical Officer of Cytosorbents Corp, received stock options contingent on regulatory approvals for DrugSorb-ATR in the US and Canada.

Vincent Capponi, President and COO of Cytosorbents Corp, received stock options that vest upon regulatory clearance of DrugSorb-ATR in the U.S. and Canada.

Peter J. Mariani, CFO of Cytosorbents Corp, reports the acquisition of stock options and restricted stock units (RSUs) as part of his compensation.

Director Edward Raymond Jones reports the acquisition of stock options in Cytosorbents Corp.

Efthymios Deliargyris, Chief Medical Officer of Cytosorbents Corp, reports acquisition of shares and stock options.

Director Alan D. Sobel reports the acquisition of 22,000 stock options in Cytosorbents Corp.